HRP20211827T1 - Kondenzirani derivati imidazola supstituirani s tercijarnim hidroksi skupinama kao inhibitori pi3k-gama - Google Patents
Kondenzirani derivati imidazola supstituirani s tercijarnim hidroksi skupinama kao inhibitori pi3k-gama Download PDFInfo
- Publication number
- HRP20211827T1 HRP20211827T1 HRP20211827TT HRP20211827T HRP20211827T1 HR P20211827 T1 HRP20211827 T1 HR P20211827T1 HR P20211827T T HRP20211827T T HR P20211827TT HR P20211827 T HRP20211827 T HR P20211827T HR P20211827 T1 HRP20211827 T1 HR P20211827T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- membered
- amino
- cycloalkyl
- imidazo
- Prior art date
Links
- 125000002887 hydroxy group Chemical group [H]O* 0.000 title 1
- 125000002883 imidazolyl group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 190
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 64
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 62
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 62
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 57
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 45
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 44
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 42
- 125000001424 substituent group Chemical group 0.000 claims 36
- 125000006721 (C5-C10) heteroaryl (C1-C6) alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 24
- 229910052805 deuterium Inorganic materials 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 17
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 16
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 11
- 101150073096 NRAS gene Proteins 0.000 claims 10
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 10
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 10
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- -1 aminosulfonylamino Chemical group 0.000 claims 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 5
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims 5
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 5
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 5
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 5
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims 5
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 5
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- HWNHQKGIFMHZHG-UHFFFAOYSA-N imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound NC(=O)c1cn2ccnc2cn1 HWNHQKGIFMHZHG-UHFFFAOYSA-N 0.000 claims 4
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 4
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 4
- AIJMGQDXUVKDIN-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxypropanamide Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(=O)N)(C(F)(F)F)O AIJMGQDXUVKDIN-UHFFFAOYSA-N 0.000 claims 3
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 3
- 201000003076 Angiosarcoma Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000001102 germinal center b cell Anatomy 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- FYTNDBMJFQRFBF-UHFFFAOYSA-N 1-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1-cyclopropyl-2,2,2-trifluoroethanol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)(F)F)(O)C1CC1 FYTNDBMJFQRFBF-UHFFFAOYSA-N 0.000 claims 1
- ZTKSBSDLRDQGEC-UHFFFAOYSA-N 1-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-2,2,2-trifluoro-1-(1-methyltetrazol-5-yl)ethanol Chemical compound CN1N=NN=C1C(O)(C1=CC(C2=CN=C3N2C=C(N=C3N)C(F)(F)F)=C(C)C=C1)C(F)(F)F ZTKSBSDLRDQGEC-UHFFFAOYSA-N 0.000 claims 1
- CNLZOTQYVVBAGU-UHFFFAOYSA-N 1-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-2,2,2-trifluoroethanol Chemical compound CC1=C(C=C(C=C1)C(O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(F)(F)F CNLZOTQYVVBAGU-UHFFFAOYSA-N 0.000 claims 1
- JJFCMBOEXQORLM-UHFFFAOYSA-N 1-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-2-fluorocyclopentan-1-ol Chemical compound CC1=C(C=C(C=C1)C1(O)CCCC1F)C1=CN=C2N1C=C(N=C2N)C(F)(F)F JJFCMBOEXQORLM-UHFFFAOYSA-N 0.000 claims 1
- UPOQEQFRJRHVGQ-UHFFFAOYSA-N 1-[8-amino-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazin-6-yl]piperidin-4-ol Chemical compound C=12C(=NC(=CN2C(=CN=1)C1=C(C)C=CC(C(O)(C)C(F)(F)F)=C1)N1CCC(CC1)O)N UPOQEQFRJRHVGQ-UHFFFAOYSA-N 0.000 claims 1
- VQOIAIVUVLWSIK-UHFFFAOYSA-N 1-[8-amino-3-[5-(1,1-difluoro-2-hydroxypropan-2-yl)-2-methylphenyl]imidazo[1,2-a]pyrazin-6-yl]piperidine-4-carbonitrile Chemical compound NC=1C=2N(C=C(N=1)N1CCC(CC1)C#N)C(=CN=2)C1=C(C=CC(=C1)C(C(F)F)(C)O)C VQOIAIVUVLWSIK-UHFFFAOYSA-N 0.000 claims 1
- VJZYVVSHLIZKAL-UHFFFAOYSA-N 2-[3-(4-amino-2-methylimidazo[2,1-f][1,2,4]triazin-7-yl)-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound C(O)(C1=CC(C=2N3N=C(N=C(N)C3=NC=2)C)=C(C)C=C1)(C)C(F)(F)F VJZYVVSHLIZKAL-UHFFFAOYSA-N 0.000 claims 1
- JALOPYVZEQSWHY-UHFFFAOYSA-N 2-[3-(4-amino-2-methylimidazo[2,1-f][1,2,4]triazin-7-yl)-4-methylphenyl]-1,1,3,3-tetrafluoropropan-2-ol Chemical compound C1(=CN=C2N1N=C(N=C2N)C)C1=C(C)C=CC(C(O)(C(F)F)C(F)F)=C1 JALOPYVZEQSWHY-UHFFFAOYSA-N 0.000 claims 1
- GLBUIWBQSOJXRJ-UHFFFAOYSA-N 2-[3-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound OC(C1=CC(C=2N3N=CN=C(N)C3=NC=2)=C(C)C=C1)(C)C(F)(F)F GLBUIWBQSOJXRJ-UHFFFAOYSA-N 0.000 claims 1
- YEVUBSDDZZVRCS-UHFFFAOYSA-N 2-[3-(8-amino-6-methylimidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)(F)F)(C)O YEVUBSDDZZVRCS-UHFFFAOYSA-N 0.000 claims 1
- YJQYZDDVSHYRLY-UHFFFAOYSA-N 2-[3-(8-amino-6-pyrimidin-5-ylimidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C=1C=NC=NC=1)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O YJQYZDDVSHYRLY-UHFFFAOYSA-N 0.000 claims 1
- YLBRSNLIYLCHDR-UHFFFAOYSA-N 2-[3-[4-[8-amino-3-[5-(1,1-difluoro-2-hydroxypropan-2-yl)-2-methylphenyl]imidazo[1,2-a]pyrazin-6-yl]pyrazol-1-yl]-1-(cyclobutanecarbonyl)azetidin-3-yl]acetonitrile Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)F)C1=CN=C2N1C=C(N=C2N)C1=CN(N=C1)C1(CC#N)CN(C1)C(=O)C1CCC1 YLBRSNLIYLCHDR-UHFFFAOYSA-N 0.000 claims 1
- RSRNWKDDJOZBSO-UHFFFAOYSA-N 2-[3-[4-amino-2-(2-methyl-1,3-oxazol-5-yl)imidazo[2,1-f][1,2,4]triazin-7-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC1=NC(=NN2C1=NC=C2C=1C=C(C=CC=1C)C(C(F)F)(C)O)C1=CN=C(O1)C RSRNWKDDJOZBSO-UHFFFAOYSA-N 0.000 claims 1
- HFIYXQQSDIYVCU-UHFFFAOYSA-N 2-[3-[4-amino-2-(2-methylpyrazol-3-yl)imidazo[2,1-f][1,2,4]triazin-7-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC1=NC(=NN2C1=NC=C2C=1C=C(C=CC=1C)C(C(F)F)(C)O)C1=CC=NN1C HFIYXQQSDIYVCU-UHFFFAOYSA-N 0.000 claims 1
- BJNJKYWCLKUSIE-UHFFFAOYSA-N 2-[3-[4-amino-2-(trifluoromethyl)imidazo[2,1-f][1,2,4]triazin-7-yl]-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound C(O)(C1=CC(C=2N3N=C(C(F)(F)F)N=C(N)C3=NC=2)=C(C)C=C1)(C)C(F)(F)F BJNJKYWCLKUSIE-UHFFFAOYSA-N 0.000 claims 1
- OGQRFUWIBQYXPY-UHFFFAOYSA-N 2-[3-[8-amino-6-(1,2,4-triazol-1-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)F)C1=CN=C2N1C=C(N=C2N)N1C=NC=N1 OGQRFUWIBQYXPY-UHFFFAOYSA-N 0.000 claims 1
- SEPRRBCVLDCSAX-UHFFFAOYSA-N 2-[3-[8-amino-6-(1,3-dimethylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CN1C=C(C(C)=N1)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F SEPRRBCVLDCSAX-UHFFFAOYSA-N 0.000 claims 1
- BSTVRXOSASBKDQ-UHFFFAOYSA-N 2-[3-[8-amino-6-(1,3-oxazol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoropropane-1,2-diol Chemical compound NC=1C=2N(C=C(N=1)C1=CN=CO1)C(=CN=2)C=1C=C(C=CC=1C)C(CO)(C(F)(F)F)O BSTVRXOSASBKDQ-UHFFFAOYSA-N 0.000 claims 1
- KNRGSGYRGQJQKB-UHFFFAOYSA-N 2-[3-[8-amino-6-(1,5-dimethylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CN1N=CC(=C1C)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F KNRGSGYRGQJQKB-UHFFFAOYSA-N 0.000 claims 1
- ACOIHWFRGXUVFL-UHFFFAOYSA-N 2-[3-[8-amino-6-(1-methylpyrazol-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=NN(C=C1)C)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O ACOIHWFRGXUVFL-UHFFFAOYSA-N 0.000 claims 1
- DXJIISJGBUZPKX-UHFFFAOYSA-N 2-[3-[8-amino-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C=1C=NN(C=1)C)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O DXJIISJGBUZPKX-UHFFFAOYSA-N 0.000 claims 1
- WWGPBAPYJSIUAN-UHFFFAOYSA-N 2-[3-[8-amino-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoropropane-1,2-diol Chemical compound NC=1C=2N(C=C(N=1)C=1C=NN(C=1)C)C(=CN=2)C=1C=C(C=CC=1C)C(CO)(C(F)(F)F)O WWGPBAPYJSIUAN-UHFFFAOYSA-N 0.000 claims 1
- PDGNBQKLRTZEED-UHFFFAOYSA-N 2-[3-[8-amino-6-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C=1C=NNC=1)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O PDGNBQKLRTZEED-UHFFFAOYSA-N 0.000 claims 1
- SSIGHBGNAKHBJB-UHFFFAOYSA-N 2-[3-[8-amino-6-(2,4-dimethylpyrazol-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CN1N=CC(C)=C1C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F SSIGHBGNAKHBJB-UHFFFAOYSA-N 0.000 claims 1
- RQRHRPQMRGHJMM-UHFFFAOYSA-N 2-[3-[8-amino-6-(2,5-dimethylpyrazol-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CN1N=C(C)C=C1C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F RQRHRPQMRGHJMM-UHFFFAOYSA-N 0.000 claims 1
- HOIBQUXHBRWEKG-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-cyclopropyl-1,3-thiazol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=CN=C(S1)C1CC1)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)(F)F)(C)O HOIBQUXHBRWEKG-UHFFFAOYSA-N 0.000 claims 1
- LWHKKLDRFTUPNH-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-cyclopropylethynyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C#CC1CC1 LWHKKLDRFTUPNH-UHFFFAOYSA-N 0.000 claims 1
- QPBDPIMVYOPVTK-FIBGUPNXSA-N 2-[3-[8-amino-6-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyrazin-3-yl]-4-(trideuteriomethyl)phenyl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C(C)(C)O)C(=CN=2)C=1C=C(C=CC=1C([2H])([2H])[2H])C(C(F)(F)F)(C)O QPBDPIMVYOPVTK-FIBGUPNXSA-N 0.000 claims 1
- BRQQUAIYOJTWNU-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxypropanamide Chemical compound CC1=C(C=C(C=C1)C(O)(C(N)=O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(C)(C)O BRQQUAIYOJTWNU-UHFFFAOYSA-N 0.000 claims 1
- RDLZUVPSLRGCKB-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-methoxypyridin-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound COC1=NC=CC=C1C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F RDLZUVPSLRGCKB-UHFFFAOYSA-N 0.000 claims 1
- RINJEEWRWUKPEI-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-methyl-1,3-oxazol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC1=NC=C(O1)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F RINJEEWRWUKPEI-UHFFFAOYSA-N 0.000 claims 1
- RQKYFZGSJSHECE-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-methyl-1,3-oxazol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoropropane-1,2-diol Chemical compound NC=1C=2N(C=C(N=1)C1=CN=C(O1)C)C(=CN=2)C=1C=C(C=CC=1C)C(CO)(C(F)(F)F)O RQKYFZGSJSHECE-UHFFFAOYSA-N 0.000 claims 1
- LBEQXIUDHUFHAL-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-methyl-1,3-thiazol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC1=NC=C(S1)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F LBEQXIUDHUFHAL-UHFFFAOYSA-N 0.000 claims 1
- USVPZTCVTWNVJK-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-methyl-1,3-thiazol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoropropane-1,2-diol Chemical compound NC=1C=2N(C=C(N=1)C1=CN=C(S1)C)C(=CN=2)C=1C=C(C=CC=1C)C(CO)(C(F)(F)F)O USVPZTCVTWNVJK-UHFFFAOYSA-N 0.000 claims 1
- GOKAHGXUXLHNAM-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-methylpyrazol-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=CC=NN1C)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)(F)F)(C(F)(F)F)O GOKAHGXUXLHNAM-UHFFFAOYSA-N 0.000 claims 1
- KUSCXKBIHZUXAE-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-methylpyrazol-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluorobutan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=CC=NN1C)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(CC)O KUSCXKBIHZUXAE-UHFFFAOYSA-N 0.000 claims 1
- SIXHPPDTYHQPJH-UHFFFAOYSA-N 2-[3-[8-amino-6-(2-methylpyrazol-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=CC=NN1C)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O SIXHPPDTYHQPJH-UHFFFAOYSA-N 0.000 claims 1
- XJOPBWCPOXABHD-UHFFFAOYSA-N 2-[3-[8-amino-6-(3,5-dimethyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC1=C(C(C)=NN1)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F XJOPBWCPOXABHD-UHFFFAOYSA-N 0.000 claims 1
- IBRPDUCSPKZNOI-UHFFFAOYSA-N 2-[3-[8-amino-6-(3-fluoro-2-methylpyridin-4-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=C(C(=NC=C1)C)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O IBRPDUCSPKZNOI-UHFFFAOYSA-N 0.000 claims 1
- IMRLYDSOPDRFCA-UHFFFAOYSA-N 2-[3-[8-amino-6-(3-methyl-1,2-oxazol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=CC(=NO1)C)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O IMRLYDSOPDRFCA-UHFFFAOYSA-N 0.000 claims 1
- MZAFTZDOCPPASU-FIBGUPNXSA-N 2-[3-[8-amino-6-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-(trideuteriomethyl)phenyl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=C3N(N=C1)CCC3)C(=CN=2)C=1C=C(C=CC=1C([2H])([2H])[2H])C(C(F)(F)F)(C)O MZAFTZDOCPPASU-FIBGUPNXSA-N 0.000 claims 1
- WUZORKHBYODKHM-UHFFFAOYSA-N 2-[3-[8-amino-6-(5-methoxy-1,3-thiazol-2-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound COC1=CN=C(S1)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)(F)F WUZORKHBYODKHM-UHFFFAOYSA-N 0.000 claims 1
- SCSXVNLILPXNDA-UHFFFAOYSA-N 2-[3-[8-amino-6-(5-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC1=NNC=C1C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F SCSXVNLILPXNDA-UHFFFAOYSA-N 0.000 claims 1
- LRIRQVVVYNRCFJ-UHFFFAOYSA-N 2-[3-[8-amino-6-(5-methylsulfonylpyridin-3-yl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C=1C=NC=C(C=1)S(=O)(=O)C)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O LRIRQVVVYNRCFJ-UHFFFAOYSA-N 0.000 claims 1
- MKGRRHINELDJHE-FIBGUPNXSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-(trideuteriomethyl)phenyl]-1,1,1-trifluoro-3-methylbutane-2,3-diol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C([2H])([2H])[2H])C(C(F)(F)F)(C(C)(O)C)O MKGRRHINELDJHE-FIBGUPNXSA-N 0.000 claims 1
- DDHIABQPNCTNPX-FIBGUPNXSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-(trideuteriomethyl)phenyl]-1,1,1-trifluorobutane-2,3-diol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C([2H])([2H])[2H])C(C(F)(F)F)(C(C)O)O DDHIABQPNCTNPX-FIBGUPNXSA-N 0.000 claims 1
- SEFNPZNTENCNMU-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-fluorophenyl]-1,1,1-trifluoropropan-2-ol Chemical compound CC(O)(C1=CC(C2=CN=C3N2C=C(N=C3N)C(F)(F)F)=C(F)C=C1)C(F)(F)F SEFNPZNTENCNMU-UHFFFAOYSA-N 0.000 claims 1
- BDQSSGFORSYFMJ-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1-trifluoro-4-(methylamino)butan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)(F)F)(CCNC)O BDQSSGFORSYFMJ-UHFFFAOYSA-N 0.000 claims 1
- QABGLAMXHIDZGT-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1-trifluoro-4-(oxan-4-ylamino)butan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)(F)F)(CCNC1CCOCC1)O QABGLAMXHIDZGT-UHFFFAOYSA-N 0.000 claims 1
- INWZFSMORTYESL-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)(F)F)(C)O INWZFSMORTYESL-UHFFFAOYSA-N 0.000 claims 1
- LOTLQNANVZIFML-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O LOTLQNANVZIFML-UHFFFAOYSA-N 0.000 claims 1
- OUGJFVMAFOQXKZ-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1-chloro-1,1-difluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)(F)Cl)C1=CN=C2N1C=C(N=C2N)C(F)(F)F OUGJFVMAFOQXKZ-UHFFFAOYSA-N 0.000 claims 1
- RLLCLUNILBCDTN-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1-fluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)CF)C1=CN=C2N1C=C(N=C2N)C(F)(F)F RLLCLUNILBCDTN-UHFFFAOYSA-N 0.000 claims 1
- MWSSHGZSOYDQFI-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxy-N-(3-methylazetidin-3-yl)propanamide Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(=O)NC1(CNC1)C)(C(F)(F)F)O MWSSHGZSOYDQFI-UHFFFAOYSA-N 0.000 claims 1
- OVZMGORTZQEAQS-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxy-N-methylpropanamide Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(=O)NC)(C(F)(F)F)O OVZMGORTZQEAQS-UHFFFAOYSA-N 0.000 claims 1
- QCKJNSZCWZNIOG-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxypropanoic acid Chemical compound CC1=C(C=C(C=C1)C(O)(C(O)=O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(F)(F)F QCKJNSZCWZNIOG-UHFFFAOYSA-N 0.000 claims 1
- IANJJQIWXJMBHK-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoropropane-1,2-diol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(CO)(C(F)(F)F)O IANJJQIWXJMBHK-UHFFFAOYSA-N 0.000 claims 1
- HDSBZJKOUWORFQ-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,4,4,4-pentafluorobutan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)(F)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(F)(F)F HDSBZJKOUWORFQ-UHFFFAOYSA-N 0.000 claims 1
- REQTYLRNIRUPDJ-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3-difluoro-2-hydroxypropanamide Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1C)C(C(=O)N)(C(F)F)O REQTYLRNIRUPDJ-UHFFFAOYSA-N 0.000 claims 1
- WZKACGWTTILADG-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-N-(1-bicyclo[1.1.1]pentanyl)-3,3,3-trifluoro-2-hydroxypropanamide Chemical compound C1(=CN=C2N1C=C(N=C2N)C(F)(F)F)C1=C(C)C=CC(C(O)(C(=O)NC23CC(C2)C3)C(F)(F)F)=C1 WZKACGWTTILADG-UHFFFAOYSA-N 0.000 claims 1
- MNLUURKZLPXCDG-UHFFFAOYSA-N 2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]phenyl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C=1C=C(C=CC=1)C(C(F)(F)F)(C)O MNLUURKZLPXCDG-UHFFFAOYSA-N 0.000 claims 1
- XTPSLLIRSJXXRH-UHFFFAOYSA-N 2-[3-[8-amino-6-[2-(hydroxymethyl)cyclopropyl]imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)F)C1=CN=C2N1C=C(N=C2N)C1CC1CO XTPSLLIRSJXXRH-UHFFFAOYSA-N 0.000 claims 1
- LGSPRNFEAYMGNC-UHFFFAOYSA-N 2-[3-[8-amino-6-[2-(hydroxymethyl)pyridin-4-yl]imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C1=CC(CO)=NC=C1 LGSPRNFEAYMGNC-UHFFFAOYSA-N 0.000 claims 1
- MATAVIMQKMNSMA-UHFFFAOYSA-N 2-[3-[8-amino-6-[2-(hydroxymethyl)pyridin-4-yl]imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)F)C1=CN=C2N1C=C(N=C2N)C1=CC(CO)=NC=C1 MATAVIMQKMNSMA-UHFFFAOYSA-N 0.000 claims 1
- SIXHPPDTYHQPJH-HPRDVNIFSA-N 2-[3-[8-amino-6-[2-(trideuteriomethyl)pyrazol-3-yl]imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C1=CC=NN1C([2H])([2H])[2H])C(=CN=2)C=1C=C(C=CC=1C)C(C(F)F)(C)O SIXHPPDTYHQPJH-HPRDVNIFSA-N 0.000 claims 1
- SZZJWXAWUJWZEG-BMSJAHLVSA-N 2-[3-[8-amino-6-[2-(trideuteriomethyl)pyrazol-3-yl]imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoropropane-1,2-diol Chemical compound NC=1C=2N(C=C(N=1)C1=CC=NN1C([2H])([2H])[2H])C(=CN=2)C=1C=C(C=CC=1C)C(CO)(C(F)(F)F)O SZZJWXAWUJWZEG-BMSJAHLVSA-N 0.000 claims 1
- NUTXPEVFWARTGU-UHFFFAOYSA-N 2-[3-[8-amino-6-[3-(hydroxymethyl)cyclobutyl]imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C1CC(CO)C1 NUTXPEVFWARTGU-UHFFFAOYSA-N 0.000 claims 1
- VSFUFCFQEFEEAD-FIBGUPNXSA-N 2-[3-[8-amino-6-[6-(1-hydroxyethyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-yl]-4-(trideuteriomethyl)phenyl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C=1C=NC(=CC=1)C(C)O)C(=CN=2)C=1C=C(C=CC=1C([2H])([2H])[2H])C(C(F)(F)F)(C)O VSFUFCFQEFEEAD-FIBGUPNXSA-N 0.000 claims 1
- QYHPWSNPVYYJRQ-UHFFFAOYSA-N 2-[3-[8-amino-6-[6-(1-hydroxyethyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC(O)C1=CC=C(C=N1)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F QYHPWSNPVYYJRQ-UHFFFAOYSA-N 0.000 claims 1
- VIRAPALVSMMMIP-UHFFFAOYSA-N 2-[3-[8-amino-6-[6-(hydroxymethyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-1,1-difluoropropan-2-ol Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)F)C1=CN=C2N1C=C(N=C2N)C1=CC=C(CO)N=C1 VIRAPALVSMMMIP-UHFFFAOYSA-N 0.000 claims 1
- DTLDMAAXGNTFOQ-UHFFFAOYSA-N 2-[4-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-1-(benzenesulfonyl)indol-6-yl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C=2N(C=C(N=1)C(F)(F)F)C(=CN=2)C1=C2C=CN(C2=CC(=C1)C(C(F)(F)F)(C)O)S(=O)(=O)C1=CC=CC=C1 DTLDMAAXGNTFOQ-UHFFFAOYSA-N 0.000 claims 1
- HZIIYHAZBHMQGF-UHFFFAOYSA-N 2-[4-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-5-methylpyridin-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound CC1=CN=C(C=C1C1=CN=C2N1C=C(N=C2N)C(F)(F)F)C(C)(O)C(F)(F)F HZIIYHAZBHMQGF-UHFFFAOYSA-N 0.000 claims 1
- CFEGAWLLXXVCKI-UHFFFAOYSA-N 2-[5-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-2-fluoro-4-methylphenyl]-1,1,1-trifluoropropan-2-ol Chemical compound CC1=CC(F)=C(C=C1C1=CN=C2N1C=C(N=C2N)C(F)(F)F)C(C)(O)C(F)(F)F CFEGAWLLXXVCKI-UHFFFAOYSA-N 0.000 claims 1
- IDQFUOQNUKIXCT-UHFFFAOYSA-N 2-[5-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-2-fluorophenyl]-1,1,1-trifluoropropan-2-ol Chemical compound N1=C2N(C(=C1)C1=CC=C(F)C(C(O)(C(F)(F)F)C)=C1)C=C(N=C2N)C(F)(F)F IDQFUOQNUKIXCT-UHFFFAOYSA-N 0.000 claims 1
- NAYISRPQBDOZLL-UHFFFAOYSA-N 2-[5-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-6-methylpyridin-3-yl]-1,1,1-trifluoropropan-2-ol Chemical compound CC1=C(C=C(C=N1)C(C)(O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(F)(F)F NAYISRPQBDOZLL-UHFFFAOYSA-N 0.000 claims 1
- YRYQAKRVSGUMGS-UHFFFAOYSA-N 2-[8-amino-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazin-6-yl]-1-morpholin-4-ylethanone Chemical compound NC=1C=2N(C=C(N=1)CC(=O)N1CCOCC1)C(=CN=2)C1=C(C=CC(=C1)C(C(F)(F)F)(C)O)C YRYQAKRVSGUMGS-UHFFFAOYSA-N 0.000 claims 1
- HQDNPWGPJIBQII-UHFFFAOYSA-N 2-[8-amino-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazin-6-yl]-N,N-dimethylacetamide Chemical compound NC=1C=2N(C=C(N=1)CC(=O)N(C)C)C(=CN=2)C1=C(C=CC(=C1)C(C(F)(F)F)(C)O)C HQDNPWGPJIBQII-UHFFFAOYSA-N 0.000 claims 1
- JWUNOCLBEFKXRD-UHFFFAOYSA-N 2-[8-amino-3-[5-(1,1-difluoro-2-hydroxypropan-2-yl)-2-methylphenyl]imidazo[1,2-a]pyrazin-6-yl]-N-(1-hydroxy-2-methylpropan-2-yl)cyclopropane-1-carboxamide Chemical compound NC=1C=2N(C=C(N=1)C1C(C1)C(=O)NC(CO)(C)C)C(=CN=2)C1=C(C=CC(=C1)C(C(F)F)(C)O)C JWUNOCLBEFKXRD-UHFFFAOYSA-N 0.000 claims 1
- URIZKMRERIRMGN-UHFFFAOYSA-N 2-[8-amino-3-[5-(1,1-difluoro-2-hydroxypropan-2-yl)-2-methylphenyl]imidazo[1,2-a]pyrazin-6-yl]-N-methylcyclopropane-1-carboxamide Chemical compound NC=1C=2N(C=C(N=1)C1C(C1)C(=O)NC)C(=CN=2)C1=C(C=CC(=C1)C(C(F)F)(C)O)C URIZKMRERIRMGN-UHFFFAOYSA-N 0.000 claims 1
- LAFXZKRNVAFLJU-UHFFFAOYSA-N 3-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-4,4,4-trifluoro-3-hydroxy-N,2,2-trimethylbutanamide Chemical compound CNC(=O)C(C)(C)C(O)(C1=CC(C2=CN=C3N2C=C(N=C3N)C(F)(F)F)=C(C)C=C1)C(F)(F)F LAFXZKRNVAFLJU-UHFFFAOYSA-N 0.000 claims 1
- HYIIEJPNGKMKNA-UHFFFAOYSA-N 3-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-4,4,4-trifluorobutane-1,3-diol Chemical compound CC1=C(C=C(C=C1)C(O)(CCO)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(F)(F)F HYIIEJPNGKMKNA-UHFFFAOYSA-N 0.000 claims 1
- MJUTXXGSBKRFCK-UHFFFAOYSA-N 3-[5-(3-acetamido-1,1,1-trifluoro-2-hydroxypropan-2-yl)-2-methylphenyl]-8-amino-N-ethylimidazo[1,2-a]pyrazine-6-carboxamide Chemical compound CC(=O)NCC(C1=CC(C=2N3C=C(C(=O)NCC)N=C(N)C3=NC=2)=C(C)C=C1)(O)C(F)(F)F MJUTXXGSBKRFCK-UHFFFAOYSA-N 0.000 claims 1
- FUKGITYOQDDYCL-UHFFFAOYSA-N 3-[8-amino-3-[5-(1,1-difluoro-2-hydroxypropan-2-yl)-2-methylphenyl]imidazo[1,2-a]pyrazin-6-yl]-4-fluorobenzamide Chemical compound NC=1C=2N(C=C(N=1)C=1C=C(C(=O)N)C=CC=1F)C(=CN=2)C1=C(C=CC(=C1)C(C(F)F)(C)O)C FUKGITYOQDDYCL-UHFFFAOYSA-N 0.000 claims 1
- ZIMYTKSWIRPFNE-UHFFFAOYSA-N 8-amino-3-[5-(3-amino-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl)-2-methylphenyl]-N-(2,3-dimethyloxolan-3-yl)imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound CC1OCCC1(C)NC(=O)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(O)(C(N)=O)C(F)(F)F ZIMYTKSWIRPFNE-UHFFFAOYSA-N 0.000 claims 1
- DCYZEOIFZLZNRS-UHFFFAOYSA-N 8-amino-3-[5-(3-amino-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl)-2-methylphenyl]-N-(3-cyclopropyloxolan-3-yl)imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound CC1=C(C=C(C=C1)C(O)(C(N)=O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(=O)NC1(CCOC1)C1CC1 DCYZEOIFZLZNRS-UHFFFAOYSA-N 0.000 claims 1
- DIDZWWGHEOVNIK-UHFFFAOYSA-N 8-amino-3-[5-(3-amino-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl)-2-methylphenyl]-N-(3-fluoro-1-bicyclo[1.1.1]pentanyl)imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound FC12CC(NC(=O)C=3N=C(N)C=4N(C(C5=CC(C(C(=O)N)(O)C(F)(F)F)=CC=C5C)=CN=4)C=3)(C1)C2 DIDZWWGHEOVNIK-UHFFFAOYSA-N 0.000 claims 1
- IHCJUPIHDIJITD-UHFFFAOYSA-N 8-amino-3-[5-(3-amino-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl)-2-methylphenyl]-N-(4-hydroxy-1-bicyclo[2.2.1]heptanyl)imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound NC=1C=2N(C=C(N=1)C(=O)NC13CCC(CC1)(C3)O)C(=CN=2)C1=C(C=CC(=C1)C(C(F)(F)F)(C(=O)N)O)C IHCJUPIHDIJITD-UHFFFAOYSA-N 0.000 claims 1
- HVPPZEIHFZVMFM-UHFFFAOYSA-N 8-amino-3-[5-(3-amino-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl)-2-methylphenyl]-N-(oxan-4-yl)imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound CC1=C(C=C(C=C1)C(O)(C(N)=O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(=O)NC1CCOCC1 HVPPZEIHFZVMFM-UHFFFAOYSA-N 0.000 claims 1
- GYOXVBYTXOJWGI-UHFFFAOYSA-N 8-amino-3-[5-(3-amino-1,1,1-trifluoro-2-hydroxy-3-oxopropan-2-yl)-2-methylphenyl]-N-[4-(trifluoromethyl)oxan-4-yl]imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound CC1=C(C=C(C=C1)C(O)(C(N)=O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(=O)NC1(CCOCC1)C(F)(F)F GYOXVBYTXOJWGI-UHFFFAOYSA-N 0.000 claims 1
- LGEVEIQPIKXMFC-UHFFFAOYSA-N 8-amino-N-(1-azabicyclo[2.2.1]heptan-4-yl)-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound NC=1C=2N(C=C(N=1)C(=O)NC13CCN(CC1)C3)C(=CN=2)C1=C(C=CC(=C1)C(C(F)(F)F)(C)O)C LGEVEIQPIKXMFC-UHFFFAOYSA-N 0.000 claims 1
- OTZYLQXEUUJHEZ-UHFFFAOYSA-N 8-amino-N-[(1-cyanocyclobutyl)methyl]-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound CC1=C(C=C(C=C1)C(C)(O)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(=O)NCC1(CCC1)C#N OTZYLQXEUUJHEZ-UHFFFAOYSA-N 0.000 claims 1
- LKNKAKXVDWROSW-UHFFFAOYSA-N 8-amino-N-[(3-methyl-1,2-oxazol-5-yl)methyl]-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound NC=1C=2N(C=C(N=1)C(=O)NCC1=CC(=NO1)C)C(=CN=2)C1=C(C=CC(=C1)C(C(F)(F)F)(C)O)C LKNKAKXVDWROSW-UHFFFAOYSA-N 0.000 claims 1
- BIHROWIPJZQHCY-UHFFFAOYSA-N 8-amino-N-[1-(hydroxymethyl)-2-oxabicyclo[2.1.1]hexan-4-yl]-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound NC=1C=2N(C=C(N=1)C(=O)NC13COC(C1)(C3)CO)C(=CN=2)C1=C(C=CC(=C1)C(C(F)(F)F)(C)O)C BIHROWIPJZQHCY-UHFFFAOYSA-N 0.000 claims 1
- XHCVERLASWIGCB-UHFFFAOYSA-N 8-amino-N-methyl-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazine-6-carboxamide Chemical compound CNC(=O)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)(F)F XHCVERLASWIGCB-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 208000017925 Askin tumor Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000033386 Buerger disease Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000010007 Cogan syndrome Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims 1
- 206010059352 Desmoid tumour Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000006050 Hemangiopericytoma Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- WCXPXLRHEUKSPF-UHFFFAOYSA-N N-[2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxypropyl]-2-fluoroacetamide Chemical compound CC1=C(C=C(C=C1)C(O)(CNC(=O)CF)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(F)(F)F WCXPXLRHEUKSPF-UHFFFAOYSA-N 0.000 claims 1
- FNUXHZZAXLONPW-UHFFFAOYSA-N N-[2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxypropyl]acetamide Chemical compound CC(=O)NCC(O)(C1=CC(C2=CN=C3N2C=C(N=C3N)C(F)(F)F)=C(C)C=C1)C(F)(F)F FNUXHZZAXLONPW-UHFFFAOYSA-N 0.000 claims 1
- IHIVOEZJPOHUTE-UHFFFAOYSA-N N-[2-[3-[8-amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl]-4-methylphenyl]-3,3,3-trifluoro-2-hydroxypropyl]benzamide Chemical compound CC1=C(C=C(C=C1)C(O)(CNC(=O)C1=CC=CC=C1)C(F)(F)F)C1=CN=C2N1C=C(N=C2N)C(F)(F)F IHIVOEZJPOHUTE-UHFFFAOYSA-N 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010073144 Peripheral primitive neuroectodermal tumour of soft tissue Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 101150107341 RERE gene Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 101100495923 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr2 gene Proteins 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 claims 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- LCHWMSVZZWVEMC-UHFFFAOYSA-N [2-[8-amino-3-[5-(1,1-difluoro-2-hydroxypropan-2-yl)-2-methylphenyl]imidazo[1,2-a]pyrazin-6-yl]cyclopropyl]-(4-methylpiperazin-1-yl)methanone Chemical compound NC=1C=2N(C=C(N=1)C1C(C1)C(=O)N1CCN(CC1)C)C(=CN=2)C1=C(C=CC(=C1)C(C(F)F)(C)O)C LCHWMSVZZWVEMC-UHFFFAOYSA-N 0.000 claims 1
- ALAOWXDMYMXQRE-UHFFFAOYSA-N [4-[8-amino-3-[5-(1,1-difluoro-2-hydroxypropan-2-yl)-2-methylphenyl]imidazo[1,2-a]pyrazin-6-yl]phenyl]boronic acid Chemical compound NC=1C=2N(C=C(N=1)C1=CC=C(C=C1)B(O)O)C(=CN=2)C1=C(C=CC(=C1)C(C(F)F)(C)O)C ALAOWXDMYMXQRE-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 201000006827 desmoid tumor Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- VLODAFYFQWFZSN-UHFFFAOYSA-N ethyl 2-[8-amino-3-[5-(1,1-difluoro-2-hydroxypropan-2-yl)-2-methylphenyl]imidazo[1,2-a]pyrazin-6-yl]cyclopropane-1-carboxylate Chemical compound CCOC(=O)C1CC1C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)F VLODAFYFQWFZSN-UHFFFAOYSA-N 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 201000009593 extraosseous chondrosarcoma Diseases 0.000 claims 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000025036 lymphosarcoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- PRXOXWAKLCYBGP-FIBGUPNXSA-N methyl 3-[4-[8-amino-3-[2-(trideuteriomethyl)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazin-6-yl]pyrazol-1-yl]-3-(cyanomethyl)cyclobutane-1-carboxylate Chemical compound NC=1C=2N(C=C(N=1)C=1C=NN(C=1)C1(CC(C1)C(=O)OC)CC#N)C(=CN=2)C1=C(C=CC(=C1)C(C(F)(F)F)(C)O)C([2H])([2H])[2H] PRXOXWAKLCYBGP-FIBGUPNXSA-N 0.000 claims 1
- CEMKXOKGWNSJLM-UHFFFAOYSA-N methyl 8-amino-3-[2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl]imidazo[1,2-a]pyrazine-6-carboxylate Chemical compound COC(=O)C1=CN2C(=CN=C2C(N)=N1)C1=C(C)C=CC(=C1)C(C)(O)C(F)(F)F CEMKXOKGWNSJLM-UHFFFAOYSA-N 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 210000003456 pulmonary alveoli Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000025185 skeletal muscle atrophy Effects 0.000 claims 1
- 230000025175 skeletal muscle hypertrophy Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000009295 smoldering myeloma Diseases 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Claims (26)
1. Spoj, naznačen time, da je predstavljen Formulom (I):
[image]
ili njegova farmaceutski prihvatljiva sol;
u kojoj:
X2 je N ili CR2;
X4 je N ili CR4;
X5 je N ili CR5;
X6 je N ili CR6;
X7 je N ili CR7;
uz uvjet da X4, X5 i X6 nisu svi N;
Y1 je C1-6 haloalkil, pri čemu se svaki halogen bira od F ili Cl, gdje je haloalkil opcionalno supstituiran s 1 ili 2 neovisno odabrana Y2 supstituenta;
R1 se bira od sljedećih: H, D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10- člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORa, SRa, NHORa, C(O)Ra, C(O)NRaRa, C(O)ORa, OC(O)Ra, OC(O)NRaRa, NRaRa, NRaNRaRa, NRaC(O)Ra, NRaC(O)ORa, NRaC(O)NRaRa, C(=NRi)Ra, C(=NRi)NRaRa, NRaC(=NRi)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(O)Ra, NRaS(O)2Ra, NRaS(O)(=NRi)Ra, NRaS(O)2NRaRa, S(O)Ra, S(O)NRaRa, S(O)2Ra, OS(O)(=NRi)Ra, SF5, P(O)RaRa, P(O)(ORa)(ORa), B(ORa)2, i S(O)2NRaRa,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od R1, opcionalno supstituiran s 1, 2, 3, 4, 5, 6, 7 ili 8 neovisno odabranih Rb supstituenata;
svaki R2, R3, R4, R5, R6 i R7 se neovisno bira od sljedećih: H, D, halogen, C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani arilC1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil, OH, NO2, amino, C1-6 alkilamino, di(C1-6 alkil)amino, tio, C1-6 alkiltio, C1-6 alkilsulfinil, C1-6 alkilsulfonil, karbamil, C1-6 alkilkarbamil, di(C1-6 alkil)karbamil, karboksi, C1-6 alkilkarbonil, C1-6 alkoksikarbonil, C1-6 alkilkarbonilamino, C1-6 alkilsulfonilamino, aminosulfonil, C1-6 alkilaminosulfonil, di(C1-6 alkil)aminosulfonil, aminosulfonilamino, C1-6 alkilaminosulfonilamino, di(C1-6 alkil)aminosulfonilamino, aminokarbonilamino, C1-6 alkilaminokarbonilamino, i di(C1-6 alkil)aminokarbonilamino,
gdje je svaki C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10 člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od R2, R3, R4, R5, R6 i R7, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rh supstituenta;
R8 se bira od sljedećih: H, D, C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, NO2, C(O)Ra, C(O)NRaRa, C(O)ORa, C(=NRi)Ra, C(=NRi)NRaRa, SF5, -P(O)RaRa, -P(O)(ORa)(ORa), B(ORa)2, i S(O)2NRaRa,
gdje je svaki C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od R8, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana R9 supstituenta;
ili bio koja dva R4 , R5, R6 i R7 supstituenta, zajedno s prstenovim atomima s kojima su vezani, tvore 4-, 5-, 6- ili 7-članu aril, cikloalkil, heteroaril, ili heterocikloalkil skupinu opcionalno supstituiranu s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta;
ili Y1 i R8, zajedno s ugljikovim atomom s kojim su vezani, tvore 4-, 5-, 6- ili 7-članu cikloalkil ili heterocikloalkil skupinu opcionalno supstituiranu s 1, 2, 3 ili 4 neovisno odabrana R9 supstituenta;
svaki R1 se neovisno bira od H, CN, OH, C1-4 alkila, i C1-4 alkoksi;
svaki Y2 se neovisno bira od sljedećih: OH, NO2, CN, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, cijano-C1-6 alkil, HO-C1-6 alkil, C1-6 alkoksi-C1-6 alkil, C3-10 cikloalkil, C1-6 alkoksi, C1-6 haloalkoksi, amino, C1-6 alkilamino, di(C1-6 alkil)amino, tio, C1-6 alkiltio, C1-6 alkilsulfinil, C1-6 alkilsulfonil, karbamil, C1-6 alkilkarbamil, di(C1-6 alkil)karbamil, karboksi, C1-6 alkilkarbonil, C1-6 alkoksikarbonil, C1-6 alkilkarbonilamino, C1-6 alkilsulfonilamino, aminosulfonil, C1-6 alkilaminosulfonil, di(C1-6 alkil)aminosulfonil, aminosulfonilamino, C1-6 alkilaminosulfonilamino, di(C1-6 alkil)aminosulfonilamino, aminokarbonilamino, C1-6 alkilaminokarbonilamino, i di(C1-6 alkil)aminokarbonilamino;
svaki Ra se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil,
C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil-, gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkilC1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od Ra, opcionalno supstituiran s 1, 2, 3, ili 4 neovisno odabrana Rb supstituenta;
svaki Rb se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORc, SRc, NHORc, C(O)Rc, C(O)NRcRc, C(O)ORc, OC(O)Rc, OC(O)NRcRc, NRcRc, NRcC(O)Rc, NRcC(O)ORc, NRcC(O)NRcRc, C(=NRi)Rc, C(=NRi)NRcRc, NRcC(=NRi)NRcRc, NRcC(=NOH)NRcRc, NRcC(=NCN)NRcRc, NRcS(O)Rc, NRcS(O)2Rc, NRcS(O)2NRcRc, S(O)Rc, S(O)NRcRc, S(O)2Rc, SF5, -P(O)RcRc, -P(O)(ORc)(ORc), B(ORc)2, i S(O)2NRcRc,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10 člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od Rb, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rd supstituenta;
svaki R9 se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORk, SRk, NHORk, C(O)Rk, C(O)NRkRk, C(O)ORk, OC(O)Rk, OC(O)NRkRk, NRkRk, NRkC(O)Rk, NRkC(O)ORk, NRkC(O)NRkRk, C(=NRi)Rk, C(=NRi)NRkRk, NRkC(=NRi)NRkRk, NRkC(=NOH)NRkRk, NRkC(=NCN)NRkRk, NRkS(O)Rk, NRkS(O)2Rk, NRkS(O)2NRkRk, S(O)Rk, S(O)NRkRk, S(O)2Rk, SF5, -P(O)RkRk, -P(O)(ORk)(ORk), B(ORk)2, i S(O)2NRkRk,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od R9, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rq supstituenta;
svaki Rc se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil-,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkilC1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od Rc, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rd supstituenta;
ili dva Rc supstituenta, zajedno s dušikovim atomom s kojim su vezani, tvore 4-, 5-, 6- ili 7-članu heteroaril ili heterocikloalkil skupinu opcionalno supstituiranu s 1, 2, 3 ili 4 neovisno odabrana Rd supstituenta;
svaki Rd se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORe, SRe, NHORe, C(O)Re, C(O)NReRe, C(O)ORe, OC(O)Re, OC(O)NReRe, NReRe, NReC(O)Re, NReC(O)ORe, NReC(O)NReRe, C(=NRi)Re, C(=NRi)NReRe, NReC(=NRi)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, NReS(O)Re, NReS(O)2Re, NReS(O)2NReRe, S(O)Re, S(O)NReRe, S(O)2Re, SF5, -P(O)ReRe, -P(O)(ORe)(ORe), B(ORe)2, i S(O)2NReRe,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkilC1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6alkil- od Rd, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rf supstituenta;
svaki Re se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil-,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil- i 4-7-člani heterocikloalkil-C1-6 alkil- od Re, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rf supstituenta;
svaki Rf se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, 4-7-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORg, SRg, NHORg, C(O)Rg, C(O)NRgRg, C(O)ORg, OC(O)Rg, OC(O)NRgRg, NRgRg, NRgC(O)Rg, NRgC(O)ORg, NRgC(O)NRgRg, C(=NRi)Rg, C(=NRi)NRgRg, NRgC(=NRi)NRgRg, NRgC(=NOH)NRgRg, NRgC(=NCN)NRgRg, NRgS(O)Rg, NRgS(O)2Rg, NRgS(O)2NRgRg, S(O)Rg, S(O)NRgRg, S(O)2Rg, SF5, -P(O) RgRg, -P(O)(ORg)(ORg), B(ORg)2, i S(O)2NRgRg,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil- od Rf, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rh supstituenta;
svaki Rg se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil-,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil- i 4-7-člani heterocikloalkil-C1-6 alkil- od Rg, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rh supstituenta;
svaki Rh se neovisno bira od sljedećih: OH, NO2, CN, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, cijano-C1-6 alkil, HO-C1-6 alkil, C1-6 alkoksi-C1-6 alkil, C3-7 cikloalkil, C1-6 alkoksi, C1-6 haloalkoksi, amino, C1-6 alkilamino, di(C1-6 alkil)amino, tio, C1-6 alkiltio, C1-6 alkilsulfinil, C1-6 alkilsulfonil, karbamil, C1-6 alkilkarbamil, di(C1-6 alkil)karbamil, karboksi, C1-6 alkilkarbonil, C1-6 alkoksikarbonil, C1-6 alkilkarbonilamino, C1-6 alkilsulfonilamino, aminosulfonil, C1-6 alkilaminosulfonil, di(C1-6 alkil)aminosulfonil, aminosulfonilamino, C1-6 alkilaminosulfonilamino, di(C1-6 alkil)aminosulfonilamino, aminokarbonilamino, C1-6 alkilaminokarbonilamino, i di(C1-6 alkil)aminokarbonilamino;
svaki Rk se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil-,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkilC1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil- i 4-10-člani heterocikloalkil-C1-6 alkil- od Rk, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rq supstituenta;
svaki Rq se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORm, SRm, NHORm, C(O)Rm, C(O)NRmRm, C(O)ORm, OC(O)Rm, OC(O)NRmRm, NHRm, NRmRm, NRmC(O)Rm, NRmC(O)ORm, NRmC(O)NRmRm, C(=NRi)Rm, C(=NRi)NRmRm, NRmC(=NRi)NRmRm, NRmC(=NOH)NRmRm, NRmC(=NCN)NRmRm, NRmS(O)Rm, NRmS(O)2Rm, NRmS(O)2NRmRm, S(O)Rm, S(O)NRmRm, S(O)2Rm, SF5, -P(O)RmRm, -P(O)(ORm)(ORm), B(ORm)2, i S(O)2NRmRm,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od Rq, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rn supstituenta;
svaki Rm se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil-,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil- i 4-7-člani heterocikloalkil-C1-6 alkil- od Rm, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rn supstituenta;
svaki Rn se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, 4-7-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORo, SRo, NHORo, C(O)Ro, C(O)NRoRo, C(O)ORo, OC(O)Ro, OC(O)NRoRo, NRoRo, NRoC(O)Ro, NRoC(O)ORo, NRoC(O)NRoRo, C(=NRi)Ro, C(=NRi)NRoRo, NRoC(=NRi)NRoRo, NRoC(=NOH)NRoRo, NRoC(=NCN)NRoRo, NRoS(O)Ro, NRoS(O)2Ro, NRoS(O)2NRoRo, S(O)Ro, S(O)NRoRo, S(O)2Ro, i S(O)2NRoRo,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil- od Rn, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rh supstituenta; i
svaki Ro se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil-, gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil- i 4-7-člani heterocikloalkil-C1-6 alkil- od Ro, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rh supstituenta.
2. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da X2 je N ili CH.
3. Spoj prema patentnom zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time, da X4 je CR4.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se R4 bira od H, D, halogena, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, i C1-6 haloalkoksi.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time, da X5 je CH.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, naznačen time, da X6 je CR6.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se R6 bira od H, D i halogena.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time, da X7 je CH.
9. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se svaki R2, R3, R4, R5, R6 i R7 neovisno bira od sljedećih: H, D, halogen, C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, CN, ORa, i SRa, gdje je svaki C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, i C1-6 haloalkoksi od R2, R3, R4, R5, R6 i R7, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rh supstituenta.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se R1 bira od sljedećih: H, D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, ORa, C(O)Ra, C(O)NRaRa, C(O)ORa, NRaRa, NRaC(O)Ra, NRaC(O)ORa, NRaC(O)NRaRa, NRaS(O)2NRaRa, NRaS(O)2Ra, S(O)2Ra, i S(O)2NRaRa,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, i 4-10-člani heterocikloalkil, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da se Y1 bira od CF3, CCl3, CF2H, CCl2H, CF2Y2, CCl2Y2, CFH2, CClH2, CFHY2, CClHY2, CF(Y2)2 i CCl(Y2)2.
12. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se R8 bira od sljedećih: H, D, C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, i 4-10-člani heterocikloalkil, gdje je svaki C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, i 4-10-člani heterocikloalkil, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana R9 supstituenta.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se R8 bira od sljedećih: H, C1-6 alkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, i C(O)NRaRa, gdje je svaki C1-6 alkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, i 4-10-člani heterocikloalkil, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana R9 supstituenta.
14. Spoj prema bilo kojem od patentnih zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3 jest H.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, naznačen time, da svaki R3, R5 i R7 jest H.
16. Spoj prema bilo kojem od patentnih zahtjeva 1 do 15, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se svaki Ra neovisno bira od sljedećih: H, D, C1-6 alkil, C1-6 haloalkil, fenil, C3-7 cikloalkil 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil-, gdje je svaki C1-6 alkil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkilC1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil- od Ra, opcionalno supstituiran s 1, 2 ili 3 neovisno odabrana Rb supstituenta.
17. Spoj prema bilo kojem od patentnih zahtjeva 1 do 16, ili njegova farmaceutski prihvatljiva sol, naznačen time, da se svaki Rb neovisno bira od sljedećih: halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, ORc, C(O)Rc, C(O)NRcRc, C(O)ORc, OC(O)Rc, OC(O)NRcRc, NRcRc, NRcC(O)Rc, NRcC(O)ORc, NRcC(O)NRcRc, S(O)Rc, S(O)NRcRc, S(O)2Rc, i S(O)2NRcRc, gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, opcionalno supstituiran s 1 ili 2 neovisno odabrana Rd supstituenta.
18. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time, da:
X2 je N ili CR2;
X4 je N ili CR4;
X5 je N ili CR5;
X6 je N ili CR6;
X7 je N ili CR7;
uz uvjet da X4, X5 i X6 nisu svi N;
Y1 je C1-6 haloalkil, pri čemu se svaki halogen bira od F ili Cl;
R1 se neovisno bira od sljedećih: H, D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10- člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORa, SRa, NHORa, C(O)Ra, C(O)NRaRa, C(O)ORa, OC(O)Ra, OC(O)NRaRa, NRaRa, NRaNRaRa, NRaC(O)Ra, NRaC(O)ORa, NRaC(O)NRaRa, C(=NRi)Ra, C(=NRi)NRaRa, NRaC(=NRi)NRaRa, NRaC(=NOH)NRaRa, NRaC(=NCN)NRaRa, NRaS(O)Ra, NRaS(O)2Ra, NRaS(O)(=NRi)Ra, NRaS(O)2NRaRa, S(O)Ra, S(O)NRaRa, S(O)2Ra, i S(O)2NRaRa,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-4 alkil- od R1, opcionalno supstituiran s 1, 2, 3, ili 4 neovisno odabranih Rb supstituenta;
svaki R2, R3, R4, R5, R6 i R7 se neovisno bira od sljedećih: H, D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani arilC1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil, OH, NO2, amino, C1-6 alkilamino, di(C1-6 alkil)amino, tio, C1-6 alkiltio, C1-6 alkilsulfinil, C1-6 alkilsulfonil, karbamil, C1-6 alkilkarbamil, di(C1-6 alkil)karbamil, karboksi, C1-6 alkilkarbonil, C1-6 alkoksikarbonil, C1-6 alkilkarbonilamino, C1-6 alkilsulfonilamino, aminosulfonil, C1-6 alkilaminosulfonil, di(C1-6 alkil)aminosulfonil, aminosulfonilamino, C1-6 alkilaminosulfonilamino, di(C1-6 alkil)aminosulfonilamino, aminokarbonilamino, C1-6 alkilaminokarbonilamino, i di(C1-6 alkil)aminokarbonilamino,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10 člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil- od R2, R3, R4 , R5, R6 i R7, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rh supstituenta;
R8 se bira od sljedećih: H, D, C1-6 alkil, C1-6 alkoksi, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, C1-6 haloalkoksi, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, NO2, C(O)Ra, C(O)NRaRa, C(O)ORa, C(=NRi)Ra, C(=NRi)NRaRa, i S(O)2NRaRa,
gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-4 alkil- od R8, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana R9 supstituenta;
ili Y1 i R8, zajedno s ugljikovim atomom s kojim su vezani, tvore 4-, 5-, 6-, ili 7-članu cikloalkil ili heterocikloalkil skupinu opcionalno supstituiranu s 1, 2, 3 ili 4 neovisno odabrana R9 supstituenta;
svaki Ri se neovisno bira od H, CN, OH, C1-4 alkila, i C1-4 alkoksi;
svaki Ra se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil-, gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkilC1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil- i 4-10-člani heterocikloalkil-C1-6 alkil- od Ra, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rb supstituenta;
svaki Rb se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORc, SRc, NHORc, C(O)Rc, C(O)NRcRc, C(O)ORc, OC(O)Rc, OC(O)NRcRc, NRcRc, NRcC(O)Rc, NRcC(O)ORc, NRcC(O)NRcRc, C(=NRi)Rc, C(=NRi)NRcRc, NRcC(=NRi)NRcRc, NRcC(=NOH)NRcRc, NRcC(=NCN)NRcRc, NRcS(O)Rc, NRcS(O)2Rc, NRcS(O)2NRcRc, S(O)Rc, S(O)NRcRc, S(O)2Rc, i S(O)2NRcRc, gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10 člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-4 alkil- od Rb, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rd supstituenta;
svaki R9 se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORk, SRk, NHORk, C(O)Rk, C(O)NRkRk, C(O)ORk, OC(O)Rk, OC(O)NRkRk, NRkRk, NRkC(O)Rk, NRkC(O)ORk, NRkC(O)NRkRk, C(=NRi)Rk, C(=NRi)NRkRk, NRkC(=NRi)NRkRk, NRkC(=NOH)NRkRk, NRkC(=NCN)NRkRk, NRkS(O)Rk, NRkS(O)2Rk, NRkS(O)2NRkRk, S(O)Rk, S(O)NRkRk, S(O)2Rk, i S(O)2NRkRk, gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-4 alkil- od R9, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rq supstituenta;
svaki Rc se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil-, gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkilC1-4 alkil-, 5-10-člani heteroaril-C1-6 alkil- i 4-10-člani heterocikloalkil-C1-6 alkil- od Rc, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rd supstituenta;
svaki Rd se neovisno bira od sljedećih: D, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, 4-10-člani heterocikloalkil-C1-6 alkil-, CN, NO2, ORe, SRe, NHORe, C(O)Re, C(O)NReRe, C(O)ORe, OC(O)Re, OC(O)NReRe, NReRe, NReC(O)Re, NReC(O)ORe, NReC(O)NReRe, C(=NRi)Re, C(=NRi)NReRe, NReC(=NRi)NReRe, NReC(=NOH)NReRe, NReC(=NCN)NReRe, NReS(O)Re, NReS(O)2Re, NReS(O)2NReRe, S(O)Re, S(O)NReRe, S(O)2Re, i S(O)2NReRe, gdje je svaki C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkilC1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-4 alkil- od Rd, opcionalno supstituiran s 1, 2, 3 ili 4 neovisno odabrana Rf supstituenta;
svaki Re se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, fenil, C3-7 cikloalkil, 5-6-člani heteroaril, 4-7-člani heterocikloalkil, fenil-C1-6 alkil-, C3-7 cikloalkil-C1-6 alkil-, 5-6-člani heteroaril-C1-6 alkil-, i 4-7-člani heterocikloalkil-C1-6 alkil-;
svaki Rh se neovisno bira od sljedećih: OH, NO2, CN, halogen, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, cijano-C1-6 alkil, HO-C1-6 alkil, alkoksi-C1-6 alkil, C3-7 cikloalkil, C1-6 alkoksi, C1-6 haloalkoksi, amino, C1-6 alkilamino, di(C1-6 alkil)amino, tio, C1-6 alkiltio, C1-6 alkilsulfinil, C1-6 alkilsulfonil, karbamil, C1-6 alkilkarbamil, di(C1-6 alkil)karbamil, karboksi, C1-6 alkilkarbonil, C1-6 alkoksikarbonil, C1-6 alkilkarbonilamino, C1-6 alkilsulfonilamino, aminosulfonil, C1-6 alkilaminosulfonil, di(C1-6 alkil)aminosulfonil, aminosulfonilamino, C1-6 alkilaminosulfonilamino, di(C1-6 alkil)aminosulfonilamino, aminokarbonilamino, C1-6 alkilaminokarbonilamino, i di(C1-6 alkil)aminokarbonilamino;
i
svaki Rk se neovisno bira od sljedećih: H, D, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, 6-10-člani aril, C3-10 cikloalkil, 5-10-člani heteroaril, 4-10-člani heterocikloalkil, 6-10-člani aril-C1-6 alkil-, C3-10 cikloalkil-C1-6 alkil-, 5-10-člani heteroaril-C1-6 alkil-, i 4-10-člani heterocikloalkil-C1-6 alkil-.
19. Spoj prema patentnom zahtjevu, naznačen time, da se bira od sljedećih:
2-(3-(4-Amino-2-(trifluorometil)imidazo[2,1-f][1,2,4]triazin-7-il)-4-metilfenil)-1,1,1 -trifluoropropan-2-ol;
2-(3-(4-Amino-2-metilimidazo[2,1 -f][1 ,2,4]triazin-7-il)-4-metilfenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(4-Aminoimidazo[2,1-f][1,2,4]triazin-7-il)-4-metilfenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-metilimidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1- trifluoropropan-2-ol;
Metil 8-amino-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-karboksilat;
8-Amino-N-metil-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)-N-((3-metilizoksazol-5-il) metil)imidazo[1,2-a]pirazin-6-karboksamid;
2-(3-(8-Amino-6-(2-(hidroksimetil)piridin-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-(2-ciklopropiltiazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-(5-metoksitiazol-2-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)1,1,1-
trifluoropropan-2-ol;
1-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-2,2,2-trifluoro-1 -(1-metil- 1H-tetrazol-5-il)etan-1-ol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1-trifluoro-4-(metilamino)butan-2-ol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1-trifluoro-4-((tetrahidro-2H-piran-4-il)amino)butan-2-ol;
3-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-4,4,4-trifluorobutan-1,3-diol;
1-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1-ciklopropil-2,2,2-trifluoroetan-1 -ol;
1-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-2,2,2-trifluoroetan-1 -ol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1-fluoropropan-2-ol;
2-(3-(8-Amino-6-(1-(metil-d3 )-1H-pirazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-( trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(2-metiloksazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1-metil-1H-pirazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
3-(8-Amino-3-(5-(1,1-difluoro-2-hidroksipropan-2-il)-2-metilfenil)imidazo[1,2-a]pirazin-6-il)-4-fluorobenzamid;
2-(3-(8-Amino-6-(pirimidin-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(2-metoksipiridin-3-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(2-metiltiazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(3-fluoro-2-metilpiridin-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1,5-dimetil-1H-pirazol-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1-metil-1H-pirazol-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1,3-dimetil-1H-pirazol-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(3 ,5-dimetil-1H-pirazol-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1H-pirazol-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1,3-dimetil-1H-pirazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1,4-dimetil-1H-pirazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1-metil-1H-pirazol-3-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(2-(hidroksimetil)piridin-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(6-(hidroksimetil)piridin-3-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(3-metil-1H-pirazol-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(3-metilizoksazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1H-1,2,4-triazol-1-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(1-metil-1H-pirazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluorobutan-2-ol;
2-(3-(4-Amino-2-(1-metil-1H-pirazol-5-il)imidazo[2,1-f][1,2,4]triazin-7-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(4-Amino-2-(2-metiloksazol-5-il)imidazo[2,1-f][1,2,4]triazin-7-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(5-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-2-fluoro-4-metilfenil)-1,1,1-trifluoropropan-2-ol;
2-(4-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-5-metilpiridin-2-il)-1,1,1-trifluoropropan-2-ol;
2-(5-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-2-fluorofenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)fenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-fluorofenil)-1,1,1-trifluoropropan-2-ol;
2-(5-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-6-metilpiridin-3-il)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,4,4,4-pentafluorobutan-2-ol;
1-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-2-fluorociklopentan-1-ol; i
8-Amino-N-(2-hidroksi-2-metilpropil)-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)-fenil)imidazo[1,2-a]pirazin-6-karboksamid;
ili njegova farmaceutski prihvatljiva sol.
20. Spoj prema patentnom zahtjevu 1, naznačen time, da se bira od sljedećih:
1-(8-Amino-3-(5-(1,1-difluoro-2-hidroksipropan-2-il)-2-metilfenil)imidazo[1,2-a]pirazin-6-il)piperidin-4-karbonitril;
l -(8-Amino-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-il)piperidin-4-ol;
2-(3-(8-Amino-6-(1-( metil-d3 )-1H-pirazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoropropan-1,2-diol;
2-(3-(8-Amino-6-(2-metiloksazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoropropan-l,2-diol;
2-(3-(8-Amino-6-(1-metil- lH-pirazol-4-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoropropan-1,2-diol;
2-(3-(8-Amino-6-(2-metiltiazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoropropan-1,2-diol;
2-(3-(8-Amino-6-(oksazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoropropan-1,2-diol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoropropan-1,2-diol;
Etil 2-(8-amino-3-( 5-(1,1-difluoro-2-hidroksipropan-2-il)-2-metilfenil)imidazo[1,2-a]pirazin-6-il)ciklopropan-1-karboksilat;
2-(8-Amino-3-(5-(1,1-difluoro-2-hidroksipropan-2-il)-2-metilfenil)imidazo[1,2-a]pirazin-6-il)-N-metilciklopropan-1-karboksamid;
(2-(8-Amino-3-(5-(1,1-difluoro-2-hidroksipropan-2-il)-2-metilfenil)imidazo[1,2-a]pirazin-6-il)ciklopropil)(4-metilpiperazin-1-il)metanon;
2-(8-Amino-3-( 5-(1,1-difluoro-2-hidroksipropan-2-il)-2-metilfenil)imidazo[1,2-a]pirazin-6-il)-N-(1-hidroksi-2-metilpropan-2-il)ciklopropan-1-karboksamid;
2-(3-(8-Amino-6-(2-(hidroksimetil)ciklopropil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol; i
8-Amino-N-(2-hidroksi-2-metilpropil)-3-(2-(metil-d3)-5-(1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-karboksamid;
ili njegova farmaceutski prihvatljiva sol.
21. Spoj prema patentnom zahtjevu 1, naznačen time, da se bira od sljedećih:
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksipropanamid;
8-Amino-3-(5-(3-amino-1,1,1-trifluoro-2-hidroksi-3-oksopropan-2-il)-2-metilfenil)-N-(3-ciklopropiltetrahidrofuran-3-il)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-3-(5-(3-amino-1,1,1-trifluoro-2-hidroksi-3-oksopropan-2-il)-2-metilfenil)-N-(2,3-dimetiltetrahidrofuran-3-il)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-3-(5-(3-amino-1,1,1-trifluoro-2-hidroksi-3-oksopropan-2-il)-2-metilfenil)-N-(4-(trifluorometil)tetrahidro-2H-piran-4-il)imidazo[1,2-a]pirazin-6-karboksamid;
3-(4-(8-Amino-3-(2-(metil-d3)-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil )imidazo[1,2-a]pirazin-6-il)-1H-pirazol- 1 -il)-3-ciklobutil propanitril;
2-(3-(8-Amino-6-(5,6-dihidro-4H-pirolo[1,2-b ]pirazol-3-il)imidazo[1,2-a]pirazin-3-il)-4-(metil-d3)fenil)-1,1,1-trifluoropropan-2-ol; i
Metil 3-(4-(8-amino-3-(2-(metil-d3)-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-il)-1H-pirazol-1-il)-3-(cijanometil)ciklobutan-1-karboksilat;
ili njegova farmaceutski prihvatljiva sol.
22. Spoj prema patentnom zahtjevu 1, naznačen time, da se bira od sljedećih:
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3-difluoro-2-hidroksipropanamid;
2-(3-(4-(8-Amino-3-( 5-(1,1-difluoro-2-hidroksipropan-2-il)-2-metilfenil)imidazo[1,2-a]pirazin-6-il)-1H-pirazol-1-il)-1-(ciklobutankarbonil)azetidin-3-il)acetonitril;
2-(3-(8-Amino-6-(5-(metilsulfonil)piridin-3-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
(4-(8-Amino-3-( 5-(1,1-difluoro-2-hidroksipropan-2-il)-2-metilfenil)imidazo[1,2-a]pirazin-6-il)fenil )boronska kiselina;
2-(3-(4-Amino-2-metilimidazo[2,1-f][1,2,4]triazin-7-il)-4-metilfenil)-1,1,3,3-tetrafluoropropan-2-ol;
((1S)-(8-Amino-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil )imidazo[1,2-a]pirazin-6-karboksamido )(ciklobutil)metil)boronska kiselina;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksi-N-metilpropanamid;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksipropanoična kiselina;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksi-N-(3-metilazetidin-3-il)propanamid;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-N-(biciklo[1.1.1]pentan-1-il)-3,3,3-trifluoro-2-hidroksipropanamid;
2-(3-(8-Amino-6-(6-(1-hidroksietil)piridin-3-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1-difluoropropan-2-ol;
2-(3-(8-Amino-6-(ciklopropiletinil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1-trifluoropropan-2-ol;
2-(8-Amino-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-il)-N,N-dimetilacetamid;
2-(8-Amino-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-il)-1-morfolinoetanon;
2-(3-(8-Amino-6-(3-(hidroksimetil)ciklobutil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1-trifluoropropan-2-ol;
N-(2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksipropil)acetamid;
N-(2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksipropil)benzamid;
N-(2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksipropil)-2-fluoroacetamid;
3-(5-(3-Acetamido-1,1,1-trifluoro-2-hidroksipropan-2-il)-2-metilfenil)-8-amino-N-etilimidazo[1,2-a]pirazin-6-karboksamid;
2-(4-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-1-(fenilsulfonil)-1H-indol-6-il)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-(metil-d3)fenil)-1,1,1-trifluorobutan-2,3-diol;
2-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-(metil-d3)fenil)-1,1,1-trifluoro-3-metilbutan-2,3-diol;
2-(3-(8-Amino-6-(2-hidroksipropan-2-il)imidazo[1,2-a]pirazin-3-il)-4-(metil-d3)fenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-(2-hidroksipropan-2-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksipropanamid;
3-(3-(8-Amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-4,4,4-trifluoro-3-hidroksi-N,2,2-trimetilbutanamid;
2-(3-(8-Amino-6-(1-metil-1H-pirazol-5-il)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1,1,1,3,3,3-heksafluoropropan-2-ol;
2-(3-(8-Amino-6-(6-(1-hidroksietil)piridin-3-il)imidazo[1,2-a]pirazin-3-il)-4-(metil-d3)fenil)-1,1,1-trifluoropropan-2-ol;
2-(3-(8-Amino-6-( trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-1-kloro-1,1-difluoropropan-2-ol;
8-Amino-N-(1-azabiciklo[2.2.1]heptan-4-il)-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-N-(3-cijanobiciklo[1.1.1]pentan-1-il)-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-N-(1-(hidroksimetil)-2-oksabiciklo[2.1.1]heksan-4-il)-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-N-((1-cijanociklobutil)metil)-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksipropan-2-il)fenil)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-3-(5-(3-amino-1,1,1-trifluoro-2-hidroksi-3-oksopropan-2-il)-2-metilfenil)-N-(2-hidroksi-2-metilpropil)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-3-(5-(3-amino-1,1,1-trifluoro-2-hidroksi-3-oksopropan-2-il)-2-metilfenil)-N-(4-hidroksibiciklo[2.2.1]heptan-1-il)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-3-(5-(3-amino-1,1,1-trifluoro-2-hidroksi-3-oksopropan-2-il)-2-metilfenil)-N-(tetrahidro-2H-piran-4-il)imidazo[1,2-a]pirazin-6-karboksamid;
8-Amino-3-(5-(3-amino-1,1,1-trifluoro-2-hidroksi-3-oksopropan-2-il)-2-metilfenil)-N-(3-fluorobiciklo[1.1.1]pentan-1-il)imidazo[1,2-a]pirazin-6-karboksamid; i
8-Amino-N-( 3-cijano-1,1,1-trifluoropropan-2-il)-3-(2-metil-5-(1,1,1-trifluoro-2-hidroksi-3-((metil-d3)amino)-3-oksopropan-2-il)fenil)imidazo[1,2-a]pirazin-6-karboksamid;
ili njegova farmaceutski prihvatljiva sol.
23. Spoj prema patentnom zahtjevu 1, naznačen time, da je to
2-(3-(8-amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksipropanamid, ili njegova farmaceutski prihvatljiva sol.
24. Spoj prema patentnom zahtjevu 1, naznačen time, da on jest
2-(3-(8-amino-6-(trifluorometil)imidazo[1,2-a]pirazin-3-il)-4-metilfenil)-3,3,3-trifluoro-2-hidroksipropanamid.
25. Farmaceutski pripravak, naznačen time, da sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 24, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivo pomoćno sredstvo ili nosač.
26. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 25, ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u postupku liječenja bolesti ili poremećaja koji su povezani s abnormalnom ekspresijom ili aktivnošću kinaze PI3Ky, pri čemu se bolest ili poremećaj bira od:
(a) autoimune bolesti ili poremećaja, raka, kardiovaskularne bolesti, ili neurodegenerativne bolesti; ili
(b) raka pluća, melanoma, raka gušterače, raka dojke, raka prostate, raka jetre, raka debelog crijeva, endometrijskog raka, raka mokraćnog mjehura, raka kože, raka maternice, raka bubrega, raka želuca, seminoma, teratokarcinoma, astrocitoma, neuroblastoma, glioma, ili sarkoma; ili
(c) Askinovog tumora, botrioidnog sarkoma, hondrosarkoma, Ewingovog sarkoma, malignog hemangioendotelioma, malignog švanoma, osteosarkoma, sarkoma mekog dijela alveole, angiosarkoma, filoidnog cistosarkoma, dermatofibrosarkoma protuberans, dezmoidnog tumora, dezmoplastičnog tumora malih okruglih stanica, epitelnog sarkoma, izvankoštanog hondrosarkoma, izvankoštanog osteosarkoma, fibrosarkoma, gastrointestinalog stromalnog tumora (GIST), hemangiopericitoma, hemangiosarkoma, Kaposijevog sarkoma, leiomiosarkoma, liposarkoma, limfangiosarkoma, limfosarkoma, malignog tumora periferne živčane ovojnice (MPNST), neurofibrosarkoma, rabdomiosarkoma, sinovijalnog sarkoma, ili nediferenciranog pleomorfnog sarkoma; ili
(d) akutne mijeloične leukemije, akutne monocitne leukemije, limfoma malih limfocita, kronične limfocitne leukemije (CLL), kronične mijeloične leukemije (CML), multiplog mijeloma, akutne limfoblastične leukemije T-stanica (T-ALL), kožnog limfoma T-stanica, velike granularne limfocitne leukemije, zrele (periferne) neoplazme T-stanice (PTCL), anaplastičnog limfoma velikih stanica (ALCL), ili limfoblastičnog limfoma; ili
(e) prolimfocitne leukemije T-stanica, granularne limfocitne leukemije T-stanica, agresivne leukemije NK-stanica, mikoze fungoida/Sezaryjevog sindroma, naplastičnog limfoma velikih stanica (tipa T-stanica), limfoma T-stanica enteropatskog tipa, leukemije/limfoma T-stanica kod odraslih, ili angioimunoblastičnog limfoma T-stanica; ili
(f) sustavnog ALCL ili primarnog kožnog ALCL; ili
(g) Burkittovog limfoma, akutne mijeloblastične leukemije, kronične mijeloične leukemije, ne-Hodgkinovog limfoma, Hodgkinovog limfoma, leukemije kosmatih stanica, limfoma plaštenih stanica, limfoma malih limfocita, folikularnog limfoma, xenoderma pigmentosum, keratoktantoma, limfoplazmacitnog limfoma, limfoma ekstranodalne marginalne zone, Waldenstromove makroglobulinemije, prolimfocitne leukemije, akutne limfoblastične leukemije, mijelofibroze, limfoma limfnog tkiva povezanog sa sluznicom (MALT), medijastinalnog (timusnog) limfoma velikih B-stanica, limfomatoidne granulomatoze, limfoma marginalne zone slezene, primarnog efuzijskog limfoma, limfoma intravaskularnih B velikih stanica, leukemija stanica plazme, ekstramedularnog plazmocitoma, tinjajućih mijeloma (aka asimptomatskog mijeloma), monoklonske gamopatije neutvrđenog značaja (MGUS), ili difuznog limfoma B velikih stanica; ili
(h) ponavljajućeg NHL, upornog NHL, periodičnog folikularnog NHL, indolentnog NHL (iNHL), ili agresivnog NHL (aNHL); ili
(i) difuznog limfoma B velikih stanica aktiviranih B limfocita (ABC), ili difuznog limfoma B velikih stanica germinativnog centra B stanica (GCB); ili
(j) endemijskog Burkittovog limfoma, sporadičnog Burkittovog limfoma, ili limfoma nalik na Burkittov limfom; ili
(k) reumatoidnog artritisa, multiple skleroze, sustavnog eritematoznog lupusa, astme, alergije, alergijskog rinitisa, pankreatitisa, psorijaze, anafilakse, glomerulonefritisa, upalne bolesti crijeva, tromboze, meningitisa, encefalitisa, dijabetičke retinopatije, benigne hipertrofije prostate, miastenije gravis, Sjögrenovog sindroma, osteoartritisa, restenoze, ili ateroskleroze; ili
(l) srčane hipertrofije, kardijske miocitne disfunkcije, akutnog koronarnog sindroma, kronične opstruktivne plućne bolesti (KOPB), kroničnog bronhitisa, povišenog krvnog tlaka, ishemije, ishemijske reperfuzije, vazokonstrikcije, anemije, bakterijske infekcije, virusne infekcije, odbacivanja usatka, bubrežne bolesti, anafilaktičkog šoka, fibroze, atrofije koštanih mišića, hipertrofije koštanih mišića, angiogeneze, sepse, bolesti usadak protiv domaćina, alogene ili ksenogene transplantacije, glomeruloskleroze, progresivne renalne fibroze, idiopatske trombocitopenijske purpure (ITP), autoimune hemolitičke anemije, vaskulitisa, sustavnog eritematoznog lupusa, lupusa nefritisa, pemfigusa, ili membranske nefropatije; ili
(m) povratne ITP ili uporne ITP; ili
(n) Behçetove bolesti, Coganovog sindroma, arteritisa divovskih stanica, reumatske polimijalgije (PMR), Takayasuovog arteritisa, Buergerove bolesti (thromboangiitis obliterans), vaskulitisa središnjeg živčanog sustava, Kawasakijeve bolesti, nodoznog poliarteritisa, Churg-Straussovog sindroma, mješovite vaskulitis krioglobulinemije (osnovne ili inducirane virusom hepatitisa C (HCV)), Henoch-Schonlein purpure (HSP), hipersenzitivnog vaskulitisa, mikroskopskog poliangiitisa, Wegenerove granulomatoze, ili sustavnog vaskulitisa (AASV) povezanog s anti-neutrofilnim citoplazmatskim protutijelima (ANCA); ili
(o) Alzheimerove bolesti, ozljede središnjeg živčanog sustava, ili moždanog udara.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762574057P | 2017-10-18 | 2017-10-18 | |
US201762608897P | 2017-12-21 | 2017-12-21 | |
US201862727316P | 2018-09-05 | 2018-09-05 | |
PCT/US2018/056311 WO2019079469A1 (en) | 2017-10-18 | 2018-10-17 | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA |
EP18797408.4A EP3697789B1 (en) | 2017-10-18 | 2018-10-17 | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211827T1 true HRP20211827T1 (hr) | 2022-03-18 |
Family
ID=64110207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211827TT HRP20211827T1 (hr) | 2017-10-18 | 2018-10-17 | Kondenzirani derivati imidazola supstituirani s tercijarnim hidroksi skupinama kao inhibitori pi3k-gama |
Country Status (33)
Country | Link |
---|---|
US (3) | US10738057B2 (hr) |
EP (2) | EP4006034A1 (hr) |
JP (2) | JP7244504B2 (hr) |
KR (1) | KR20200089264A (hr) |
CN (1) | CN111542526B (hr) |
AU (2) | AU2018350980B2 (hr) |
BR (1) | BR112020007593A2 (hr) |
CA (1) | CA3084589A1 (hr) |
CL (1) | CL2020001047A1 (hr) |
CR (2) | CR20210442A (hr) |
CY (1) | CY1124814T1 (hr) |
EC (1) | ECSP20024651A (hr) |
ES (1) | ES2902390T3 (hr) |
GE (1) | GEP20237483B (hr) |
HR (1) | HRP20211827T1 (hr) |
HU (1) | HUE056615T2 (hr) |
IL (3) | IL295978B2 (hr) |
JO (1) | JOP20200086A1 (hr) |
LT (1) | LT3697789T (hr) |
MA (1) | MA50398B1 (hr) |
MD (1) | MD3697789T2 (hr) |
MX (1) | MX2020003862A (hr) |
PE (1) | PE20210169A1 (hr) |
PH (1) | PH12020550442A1 (hr) |
PL (1) | PL3697789T3 (hr) |
PT (1) | PT3697789T (hr) |
RS (1) | RS62818B1 (hr) |
SG (1) | SG11202003428VA (hr) |
SI (1) | SI3697789T1 (hr) |
TW (1) | TWI803525B (hr) |
UA (1) | UA128085C2 (hr) |
WO (1) | WO2019079469A1 (hr) |
ZA (1) | ZA202201220B (hr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202003428VA (en) | 2017-10-18 | 2020-05-28 | Incyte Corp | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
PL3728271T3 (pl) | 2017-12-19 | 2023-01-23 | Turning Point Therapeutics, Inc. | Związki makrocykliczne do leczenia chorób |
ES2910071T3 (es) * | 2018-03-08 | 2022-05-11 | Incyte Corp | Compuestos de aminopirazina diol como inhibidores de PI3K-Y |
GEP20237560B (en) | 2018-07-05 | 2023-10-25 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
CR20210165A (es) * | 2018-09-05 | 2021-10-01 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico |
CN115286521B (zh) * | 2022-07-11 | 2023-11-03 | 上海医药集团(本溪)北方药业有限公司 | 一种盐酸左沙丁胺醇的合成方法 |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4269846A (en) | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0011092D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (III) |
CN1321628C (zh) | 2000-06-28 | 2007-06-20 | 史密斯克莱·比奇曼公司 | 湿磨方法 |
DE60230890D1 (de) | 2001-09-19 | 2009-03-05 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
AU2002334217B2 (en) | 2001-10-26 | 2008-07-03 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
DE10207843A1 (de) | 2002-02-15 | 2003-09-04 | Schering Ag | Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7186832B2 (en) * | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
EP1599474B1 (en) | 2003-03-04 | 2013-04-24 | California Institute Of Technology | Heterocyclic oligomeric compounds for DNA recognition |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
CN1829709A (zh) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | 对抗黄病毒的双环咪唑衍生物 |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
JP4916883B2 (ja) * | 2003-10-15 | 2012-04-18 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
TW200610762A (en) | 2004-06-10 | 2006-04-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
CA2617557A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
EP1928237A4 (en) | 2005-09-02 | 2011-03-09 | Abbott Lab | NEW HETEROCYCLES BASED ON IMIDAZO |
ATE456565T1 (de) | 2006-06-22 | 2010-02-15 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren |
US20090131481A1 (en) | 2007-03-27 | 2009-05-21 | Paratek Pharmaceuticals, Inc. | Transcription Factor Modulating Compounds and Methods of Use Thereof |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
CA2704599C (en) | 2007-11-16 | 2015-05-12 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
EP2234486A4 (en) | 2007-12-19 | 2011-09-14 | Scripps Research Inst | BENZIMIDAZOLE AND ANALOGUE AS RHO-KINASEHEMMER |
EP2240023A4 (en) | 2008-01-15 | 2010-12-29 | Siga Technologies Inc | ANTIVIRAL DRUGS FOR THE TREATMENT OF ARENA VIRUS INFECTIONS |
EP2257161B1 (en) | 2008-02-26 | 2012-04-25 | Merck Sharp & Dohme Corp. | Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia |
SI2288610T1 (sl) | 2008-03-11 | 2016-11-30 | Incyte Holdings Corporation | Derivati azetidina in ciklobutana kot inhibitorji jak |
WO2009133127A1 (en) | 2008-04-30 | 2009-11-05 | Merck Serono S.A. | Fused bicyclic compounds and use thereof as pi3k inhibitors |
WO2009158118A2 (en) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
US8470819B2 (en) | 2008-11-03 | 2013-06-25 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
TW201028399A (en) | 2008-11-27 | 2010-08-01 | Shionogi & Co | Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity |
GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
EP2401273A1 (en) | 2009-02-27 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
CA2756759C (en) * | 2009-04-16 | 2017-11-07 | Joaquin Pastor Fernandez | Imidazopyrazines for use as kinase inhibitors |
EA025520B1 (ru) | 2009-05-22 | 2017-01-30 | Инсайт Холдингс Корпорейшн | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ |
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011075630A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
EP2552208A4 (en) | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
EP2575866A4 (en) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
EP2627650A2 (en) | 2010-05-26 | 2013-08-21 | Merck Sharp & Dohme Corp. | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
EP2627181A4 (en) | 2010-10-13 | 2014-03-19 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
US8729102B2 (en) | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US8673905B2 (en) | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
US9029389B2 (en) | 2011-04-21 | 2015-05-12 | Institut Pasteur Korea | Anti-inflammation compounds |
AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
SI2751109T1 (sl) | 2011-09-02 | 2017-03-31 | Incyte Holdings Corporation | Heterociklilamini kot inhibitorji pi3k |
CN104066735B (zh) | 2012-01-10 | 2016-08-31 | 拜耳知识产权有限责任公司 | 作为akt激酶抑制剂的取代的咪唑并吡嗪 |
US9212169B2 (en) | 2012-03-01 | 2015-12-15 | Hyogo College Of Medicine | Benzimidazole derivative and use thereof |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
JP6217629B2 (ja) | 2012-05-31 | 2017-10-25 | 住友化学株式会社 | 縮合複素環化合物 |
ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
TWI657090B (zh) | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
WO2014149207A2 (en) | 2013-03-15 | 2014-09-25 | Dow Agrosciences Llc | Benzimidazole-based insecticidal compositions and related methods |
EP2976077A4 (en) | 2013-03-22 | 2016-11-30 | Scripps Research Inst | BENZIMIDAZOLES SUBSTITUTED AS MODULATORS OF A NOCICEPTIN RECEPTOR |
US9394254B2 (en) | 2013-05-08 | 2016-07-19 | The University of Denver and Regis University | Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase |
PE20160126A1 (es) | 2013-05-17 | 2016-02-24 | Incyte Corp | Derivados del bipirazol como inhibidores jak |
EP4219477A1 (en) | 2013-07-17 | 2023-08-02 | Otsuka Pharmaceutical Co., Ltd. | Cyanotriazole compounds |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20220066179A (ko) | 2014-04-08 | 2022-05-23 | 인사이트 코포레이션 | Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료 |
EP2930048A1 (en) | 2014-04-10 | 2015-10-14 | Johnson Controls Automotive Electronics SAS | Head up display projecting visual information onto a screen |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
EA201790502A1 (ru) | 2014-09-16 | 2017-10-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы гистоновых диметилаз |
WO2016064958A1 (en) * | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors |
EP3209664B1 (en) | 2014-10-22 | 2020-06-03 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds as pi3k inhibitors |
MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
WO2016106624A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
US9968604B2 (en) * | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
KR20180003614A (ko) | 2015-05-12 | 2018-01-09 | 카리라 파마슈티컬스, 아이앤씨. | 바이사이클릭 화합물 |
TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
WO2017223414A1 (en) * | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
MX2019002281A (es) | 2016-08-26 | 2019-06-20 | Mitsubishi Tanabe Pharma Corp | Compuesto heterociclico nitrogenado biciclico. |
US20200000713A1 (en) | 2017-01-20 | 2020-01-02 | Massachusetts Institute Of Technology | Injectable polymer micro-depots for controlled local drug delivery |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
CN111094243B (zh) | 2017-07-24 | 2023-09-05 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
SG11202003428VA (en) | 2017-10-18 | 2020-05-28 | Incyte Corp | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
MA50418A (fr) | 2017-10-18 | 2021-04-07 | Epizyme Inc | Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse |
PL3728271T3 (pl) | 2017-12-19 | 2023-01-23 | Turning Point Therapeutics, Inc. | Związki makrocykliczne do leczenia chorób |
LT3728254T (lt) | 2017-12-21 | 2023-05-10 | Boehringer Ingelheim International Gmbh | Naujieji benzilaminu pakeistieji piridopirimidinonai ir jų dariniai kaip sos1 inhibitoriai |
CN111491925B (zh) | 2017-12-21 | 2023-12-29 | 巴斯夫欧洲公司 | 杀害虫化合物 |
CR20210165A (es) * | 2018-09-05 | 2021-10-01 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico |
-
2018
- 2018-10-17 SG SG11202003428VA patent/SG11202003428VA/en unknown
- 2018-10-17 JP JP2020521911A patent/JP7244504B2/ja active Active
- 2018-10-17 GE GEAP201815327A patent/GEP20237483B/en unknown
- 2018-10-17 SI SI201830506T patent/SI3697789T1/sl unknown
- 2018-10-17 AU AU2018350980A patent/AU2018350980B2/en active Active
- 2018-10-17 CR CR20210442A patent/CR20210442A/es unknown
- 2018-10-17 HU HUE18797408A patent/HUE056615T2/hu unknown
- 2018-10-17 IL IL295978A patent/IL295978B2/en unknown
- 2018-10-17 CA CA3084589A patent/CA3084589A1/en active Pending
- 2018-10-17 TW TW107136622A patent/TWI803525B/zh active
- 2018-10-17 US US16/163,341 patent/US10738057B2/en active Active
- 2018-10-17 HR HRP20211827TT patent/HRP20211827T1/hr unknown
- 2018-10-17 EP EP21196484.6A patent/EP4006034A1/en active Pending
- 2018-10-17 WO PCT/US2018/056311 patent/WO2019079469A1/en active Application Filing
- 2018-10-17 MX MX2020003862A patent/MX2020003862A/es unknown
- 2018-10-17 EP EP18797408.4A patent/EP3697789B1/en active Active
- 2018-10-17 CN CN201880081276.3A patent/CN111542526B/zh active Active
- 2018-10-17 BR BR112020007593-0A patent/BR112020007593A2/pt unknown
- 2018-10-17 MD MDE20200857T patent/MD3697789T2/ro unknown
- 2018-10-17 KR KR1020207014142A patent/KR20200089264A/ko not_active Application Discontinuation
- 2018-10-17 JO JOP/2020/0086A patent/JOP20200086A1/ar unknown
- 2018-10-17 CR CR20200214A patent/CR20200214A/es unknown
- 2018-10-17 RS RS20211581A patent/RS62818B1/sr unknown
- 2018-10-17 MA MA50398A patent/MA50398B1/fr unknown
- 2018-10-17 PE PE2020000403A patent/PE20210169A1/es unknown
- 2018-10-17 UA UAA202002916A patent/UA128085C2/uk unknown
- 2018-10-17 PL PL18797408T patent/PL3697789T3/pl unknown
- 2018-10-17 LT LTEPPCT/US2018/056311T patent/LT3697789T/lt unknown
- 2018-10-17 ES ES18797408T patent/ES2902390T3/es active Active
- 2018-10-17 IL IL295978A patent/IL295978B1/en unknown
- 2018-10-17 PT PT187974084T patent/PT3697789T/pt unknown
-
2020
- 2020-04-16 IL IL273983A patent/IL273983B2/en unknown
- 2020-04-17 PH PH12020550442A patent/PH12020550442A1/en unknown
- 2020-04-17 CL CL2020001047A patent/CL2020001047A1/es unknown
- 2020-05-04 EC ECSENADI202024651A patent/ECSP20024651A/es unknown
- 2020-06-26 US US16/913,488 patent/US11225486B2/en active Active
-
2021
- 2021-11-30 US US17/537,674 patent/US11926630B2/en active Active
- 2021-12-03 CY CY20211101062T patent/CY1124814T1/el unknown
-
2022
- 2022-01-26 ZA ZA2022/01220A patent/ZA202201220B/en unknown
-
2023
- 2023-03-09 JP JP2023036727A patent/JP2023085290A/ja active Pending
- 2023-05-17 AU AU2023203088A patent/AU2023203088A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211827T1 (hr) | Kondenzirani derivati imidazola supstituirani s tercijarnim hidroksi skupinama kao inhibitori pi3k-gama | |
HRP20220331T1 (hr) | Spojevi aminopirazin diola kao inhibitori pi3k-y | |
JP2017052805A5 (hr) | ||
JP2021500340A5 (hr) | ||
HRP20210627T1 (hr) | Heterociklilamini kao inhibitori pi3k | |
HRP20220599T1 (hr) | Heterociklički spojevi kao inhibitori pi3k-gama | |
JP2018044008A5 (hr) | ||
HRP20130106T1 (hr) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
JP2015527387A5 (hr) | ||
HRP20161177T1 (hr) | Modulator glukagonskog receptora | |
JP2011252024A5 (hr) | ||
HRP20110097T1 (hr) | Derivati fenilpirazola kao nesteroidni ligandi glukokortikoidnih receptora | |
RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
HRP20231614T1 (hr) | Spojevi pirolotriazina kao tam inhibitori | |
JP2015509975A5 (hr) | ||
JP2018515438A5 (hr) | ||
HRP20160112T1 (hr) | HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE | |
JP2013515729A5 (hr) | ||
JP2013514356A5 (hr) | ||
JP2017533968A5 (hr) | ||
JP2015531366A5 (hr) | ||
CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
HRP20140309T1 (hr) | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE | |
JP2013528204A5 (hr) | ||
JP2014512404A5 (hr) |